These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 33973246)

  • 1. Normalisation of glucose metabolism by exendin-4 in the chronic phase after stroke promotes functional recovery in male diabetic mice.
    Augestad IL; Dekens D; Karampatsi D; Elabi O; Zabala A; Pintana H; Larsson M; Nyström T; Paul G; Darsalia V; Patrone C
    Br J Pharmacol; 2022 Feb; 179(4):677-694. PubMed ID: 33973246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity-induced type 2 diabetes impairs neurological recovery after stroke in correlation with decreased neurogenesis and persistent atrophy of parvalbumin-positive interneurons.
    Pintana H; Lietzau G; Augestad IL; Chiazza F; Nyström T; Patrone C; Darsalia V
    Clin Sci (Lond); 2019 Jul; 133(13):1367-1386. PubMed ID: 31235555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of Glycemia in the Recovery Phase After Stroke Counteracts the Detrimental Effect of Obesity-Induced Type 2 Diabetes on Neurological Recovery.
    Augestad IL; Pintana H; Larsson M; Krizhanovskii C; Nyström T; Klein T; Darsalia V; Patrone C
    Diabetes; 2020 Sep; 69(9):1961-1973. PubMed ID: 32540876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 2 diabetes-induced neuronal pathology in the piriform cortex of the rat is reversed by the GLP-1 receptor agonist exendin-4.
    Lietzau G; Nyström T; Östenson CG; Darsalia V; Patrone C
    Oncotarget; 2016 Feb; 7(5):5865-76. PubMed ID: 26744321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diet-induced weight loss in obese/diabetic mice normalizes glucose metabolism and promotes functional recovery after stroke.
    Karampatsi D; Zabala A; Wilhelmsson U; Dekens D; Vercalsteren E; Larsson M; Nyström T; Pekny M; Patrone C; Darsalia V
    Cardiovasc Diabetol; 2021 Dec; 20(1):240. PubMed ID: 34937562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes negatively affects cortical and striatal GABAergic neurons: an effect that is partially counteracted by exendin-4.
    Larsson M; Lietzau G; Nathanson D; Östenson CG; Mallard C; Johansson ME; Nyström T; Patrone C; Darsalia V
    Biosci Rep; 2016 Dec; 36(6):. PubMed ID: 27780892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-1 (GLP-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke.
    Nizari S; Basalay M; Chapman P; Korte N; Korsak A; Christie IN; Theparambil SM; Davidson SM; Reimann F; Trapp S; Yellon DM; Gourine AV
    Basic Res Cardiol; 2021 May; 116(1):32. PubMed ID: 33942194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP-1 receptor nitration contributes to loss of brain pericyte function in a mouse model of diabetes.
    Bailey J; Coucha M; Bolduc DR; Burnett FN; Barrett AC; Ghaly M; Abdelsaid M
    Diabetologia; 2022 Sep; 65(9):1541-1554. PubMed ID: 35687178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of glia in the physiology and pharmacology of glucagon-like peptide-1: implications for obesity, diabetes, neurodegeneration and glaucoma.
    Cui QN; Stein LM; Fortin SM; Hayes MR
    Br J Pharmacol; 2022 Feb; 179(4):715-726. PubMed ID: 34519040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats.
    Darsalia V; Mansouri S; Ortsäter H; Olverling A; Nozadze N; Kappe C; Iverfeldt K; Tracy LM; Grankvist N; Sjöholm Å; Patrone C
    Clin Sci (Lond); 2012 May; 122(10):473-83. PubMed ID: 22150224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice.
    Vercalsteren E; Karampatsi D; Buizza C; Nyström T; Klein T; Paul G; Patrone C; Darsalia V
    Cardiovasc Diabetol; 2024 Feb; 23(1):88. PubMed ID: 38424560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
    Lee CH; Jeon SJ; Cho KS; Moon E; Sapkota A; Jun HS; Ryu JH; Choi JW
    Mol Neurobiol; 2018 Apr; 55(4):3007-3020. PubMed ID: 28456941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study.
    Mao D; Cao H; Shi M; Wang CC; Kwong J; Li JJX; Hou Y; Ming X; Lee HM; Tian XY; Wong CK; Chow E; Kong APS; Lui VWY; Chan PKS; Chan JCN
    EBioMedicine; 2021 Mar; 65():103242. PubMed ID: 33684886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain GLP-1/IGF-1 Signaling and Autophagy Mediate Exendin-4 Protection Against Apoptosis in Type 2 Diabetic Rats.
    Candeias E; Sebastião I; Cardoso S; Carvalho C; Santos MS; Oliveira CR; Moreira PI; Duarte AI
    Mol Neurobiol; 2018 May; 55(5):4030-4050. PubMed ID: 28573460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study.
    Gaborit B; Julla JB; Besbes S; Proust M; Vincentelli C; Alos B; Ancel P; Alzaid F; Garcia R; Mailly P; Sabatier F; Righini M; Gascon P; Matonti F; Houssays M; Goumidi L; Vignaud L; Guillonneau X; Erginay A; Dupas B; Marie-Louise J; Autié M; Vidal-Trecan T; Riveline JP; Venteclef N; Massin P; Muller L; Dutour A; Gautier JF; Germain S
    J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 31589290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor.
    Helmstädter J; Keppeler K; Küster L; Münzel T; Daiber A; Steven S
    Br J Pharmacol; 2022 Feb; 179(4):659-676. PubMed ID: 33764504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics.
    Kabahizi A; Wallace B; Lieu L; Chau D; Dong Y; Hwang ES; Williams KW
    Br J Pharmacol; 2022 Feb; 179(4):600-624. PubMed ID: 34519026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide-YY
    Boland BB; Laker RC; O'Brien S; Sitaula S; Sermadiras I; Nielsen JC; Barkholt P; Roostalu U; Hecksher-Sørensen J; Sejthen SR; Thorbek DD; Suckow A; Burmeister N; Oldham S; Will S; Howard VG; Gill BM; Newton P; Naylor J; Hornigold DC; Austin J; Lantier L; McGuinness OP; Trevaskis JL; Grimsby JS; Rhodes CJ
    Mol Metab; 2022 Jan; 55():101392. PubMed ID: 34781035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization.
    Darsalia V; Hua S; Larsson M; Mallard C; Nathanson D; Nyström T; Sjöholm Å; Johansson ME; Patrone C
    PLoS One; 2014; 9(8):e103114. PubMed ID: 25101679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders.
    Hölscher C
    Br J Pharmacol; 2022 Feb; 179(4):695-714. PubMed ID: 33900631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.